INMUNE BIO INC.: stockholders equity
Stockholders equity for INMUNE BIO INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All INMUNE BIO INC. financial histories
What this measure means
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
Exact concept: us-gaap:StockholdersEquity. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2016-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 23,524,000 | USD | 2026-03-30 | 10-K · 0001213900-26-036370 |
| At date | 2024-12-31 | 32,097,000 | USD | 2026-03-30 | 10-K · 0001213900-26-036370 |
| At date | 2023-12-31 | 37,340,000 | USD | 2026-03-30 | 10-K · 0001213900-26-036370 |
| At date | 2022-12-31 | 60,104,000 | USD | 2025-03-27 | 10-K · 0001013762-25-003354 |
| At date | 2021-12-31 | 80,225,000 | USD | 2024-03-28 | 10-K · 0001213900-24-027206 |
| At date | 2020-12-31 | 38,754,000 | USD | 2023-03-02 | 10-K · 0001213900-23-016875 |
| At date | 2019-12-31 | 23,610,000 | USD | 2022-03-03 | 10-K · 0001213900-22-010573 |
| At date | 2018-12-31 | 16,539,576 | USD | 2021-03-04 | 10-K · 0001213900-21-013456 |
| At date | 2017-12-31 | 18,103,753 | USD | 2020-03-11 | 10-K · 0001213900-20-005916 |
| At date | 2016-12-31 | -149,203 | USD | 2019-03-29 | 10-K · 0001640334-19-000466 |
Related financial histories
- INMUNE BIO INC.: total assets
- INMUNE BIO INC.: total liabilities
- INMUNE BIO INC.: cash and cash equivalents
- INMUNE BIO INC.: net income or loss
- INMUNE BIO INC.: operating cash flow
- INMUNE BIO INC.: revenue
- INMUNE BIO INC.: financing cash flow
- INMUNE BIO INC.: investing cash flow
- INMUNE BIO INC.: retained earnings or deficit
- INMUNE BIO INC.: basic weighted-average shares
- INMUNE BIO INC.: diluted weighted-average shares
- INMUNE BIO INC.: basic earnings per share
- INMUNE BIO INC.: diluted earnings per share
- INMUNE BIO INC.: share-based compensation expense
- INMUNE BIO INC.: operating income or loss
- INMUNE BIO INC.: current assets
- INMUNE BIO INC.: interest expense
- INMUNE BIO INC.: current liabilities
- INMUNE BIO INC.: net current accounts receivable
- INMUNE BIO INC.: operating expenses
- INMUNE BIO INC.: research and development expense
Inspect the source
- Entity
- INMUNE BIO INC. / CIK 0001711754
- Captured
- 2026-09-21T17:24:27.593Z
- SEC response SHA-256
aa396b13e085ef151a75bc6c09f236f07d824422291af8c81051485dff3f082e
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001711754.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))